The Analgesic Activity of Morphine-6-glucuronide

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 1992 Aug 1

PMID 1419474

Citations 49

Authors

R Osborne

P Thompson

S Joel

D TREW

N Patel

M Slevin

Affiliations

Soon will be listed here.

Abstract

1. The pharmacokinetics, cardio-respiratory effects and analgesic effects of intravenous morphine-6-glucuronide were studied in 20 cancer patients with pain. Four different dose levels (0.5, 1, 2, and 4 mg 70 kg-1) were studied. Plasma concentrations of morphine-6-glucuronide were measured for 12 h after dosing. Pulse rate, respiratory rate and blood pressure were monitored, and pain relief was measured using two rating scales and a visual analogue scale. 2. The mean elimination half-life (+/- s.d.) of morphine-6-glucuronide was 3.2 +/- 1.6 h. The mean AUC standardised to a dose of 1 mg 70 kg-1 was 390 +/- 263 nmol l-1 h. Mean morphine-6-glucuronide clearance was 96 +/- 38 ml min-1. There was a direct relationship between morphine-6-glucuronide plasma clearance and calculated creatinine clearance (r = 0.81, P less than 0.001). 38 +/- 22% of the dose of morphine-6-glucuronide was recovered unchanged in the urine in 24 h. No morphine or morphine-3-glucuronide was detected in the plasma or urine of any patient after morphine-6-glucuronide treatment. 3. Morphine-6-glucuronide exerted a useful analgesic effect in 17/19 assessable patients for periods ranging between 2 and 24 h. No correlation was observed between dose or plasma morphine-6-glucuronide concentrations, and duration or degree of analgesia. No clinically significant changes in cardio-respiratory parameters were observed. No patients reported sedation or euphoria. Nausea and vomiting were notably absent in all cases. 4. Morphine-6-glucuronide is an effective and well-tolerated analgesic. It is likely that the majority of the therapeutic benefit of morphine is mediated by morphine-6-glucuronide.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Pharmacokinetics and thermal anti-nociceptive effects of oral morphine in horses.

Knych H, Steinmetz S, Traynham M, McKemie D, Kass P Front Vet Sci. 2024; 11:1461648.

PMID: 39355143 PMC: 11443510. DOI: 10.3389/fvets.2024.1461648.

Hydrocodone, Oxycodone, and Morphine Metabolism and Drug-Drug Interactions.

Coates S, Lazarus P J Pharmacol Exp Ther. 2023; 387(2):150-169.

PMID: 37679047 PMC: 10586512. DOI: 10.1124/jpet.123.001651.

Heroin and its metabolites: relevance to heroin use disorder.

Milella M, DOttavio G, De Pirro S, Barra M, Caprioli D, Badiani A Transl Psychiatry. 2023; 13(1):120.

PMID: 37031205 PMC: 10082801. DOI: 10.1038/s41398-023-02406-5.

Changes in Plasma Metabolic Signature upon Acute and Chronic Morphine Administration in Morphine-Tolerant Mice.

Kutchy N, Palermo A, Ma R, Li Z, Ulanov A, Callen S Metabolites. 2023; 13(3).

PMID: 36984873 PMC: 10053579. DOI: 10.3390/metabo13030434.

Machine learning and structure-based modeling for the prediction of UDP-glucuronosyltransferase inhibition.

Dudas B, Bagdad Y, Picard M, Perahia D, Miteva M iScience. 2022; 25(11):105290.

PMID: 36304105 PMC: 9593791. DOI: 10.1016/j.isci.2022.105290.

References

Rigg J . Ventilatory effects and plasma concentration of morphine in man. Br J Anaesth. 1978; 50(8):759-65. DOI: 10.1093/bja/50.8.759. View

Woods L . Distribution and fate of morphine in non-tolerant and tolerant dogs and rats. J Pharmacol Exp Ther. 1954; 112(2):158-75. View

Osborne R, Joel S, TREW D, Slevin M . Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther. 1990; 47(1):12-9. DOI: 10.1038/clpt.1990.2. View

Pasternak G, Bodnar R, Clark J, Inturrisi C . Morphine-6-glucuronide, a potent mu agonist. Life Sci. 1987; 41(26):2845-9. DOI: 10.1016/0024-3205(87)90431-0. View

Pasternak G, Wood P . Multiple mu opiate receptors. Life Sci. 1986; 38(21):1889-98. DOI: 10.1016/0024-3205(86)90217-1. View

Osborne R, Joel S, Slevin M . Morphine intoxication in renal failure: the role of morphine-6-glucuronide. Br Med J (Clin Res Ed). 1986; 292(6535):1548-9. PMC: 1340555. DOI: 10.1136/bmj.292.6535.1548. View

Samuelsson H, Nordberg G, Hedner T, Lindqvist J . CSF and plasma morphine concentrations in cancer patients during chronic epidural morphine therapy and its relation to pain relief. Pain. 1987; 30(3):303-310. DOI: 10.1016/0304-3959(87)90018-2. View

Brown C, Roerig S, Burger V, Cody Jr R, FUJIMOTO J . Analgesic potencies of morphine 3- and 6-sulfates after intracerebroventricular administration in mice: relationship to structural characteristics defined by mass spectrometry and nuclear magnetic resonance. J Pharm Sci. 1985; 74(8):821-4. DOI: 10.1002/jps.2600740804. View

Shimomura K, KAMATA O, Ueki S, Ida S, Oguri K, Yoshimura H . Analgesic effect of morphine glucuronides. Tohoku J Exp Med. 1971; 105(1):45-52. DOI: 10.1620/tjem.105.45. View

10.

Yoshimura H, Oguri K, Tsukamoto H . Metabolism of drugs. LX. The synthesis of codeine and morphine glucuronides. Chem Pharm Bull (Tokyo). 1968; 16(11):2114-9. DOI: 10.1248/cpb.16.2114. View

11.

Johnston A, Woollard R . STRIPE: an interactive computer program for the analysis of drug pharmacokinetics. J Pharmacol Methods. 1983; 9(3):193-9. DOI: 10.1016/0160-5402(83)90038-4. View

12.

Sawe J, Dahlstrom B, Rane A . Steady-state kinetics and analgesic effect of oral morphine in cancer patients. Eur J Clin Pharmacol. 1983; 24(4):537-42. DOI: 10.1007/BF00609900. View

13.

Janssen P . A review of the chemical features associated with strong morphine-like activity. Br J Anaesth. 1962; 34:260-8. DOI: 10.1093/bja/34.4.260. View

14.

Boerner U . The metabolism of morphine and heroin in man. Drug Metab Rev. 1975; 4(1):39-73. DOI: 10.3109/03602537508993748. View

15.

Hanna M, Peat S, Knibb A, Fung C . Disposition of morphine-6-glucuronide and morphine in healthy volunteers. Br J Anaesth. 1991; 66(1):103-7. DOI: 10.1093/bja/66.1.103. View

16.

Bodd E, Jacobsen D, Lund E, Ripel A, Morland J . Morphine-6-glucuronide might mediate the prolonged opioid effect of morphine in acute renal failure. Hum Exp Toxicol. 1990; 9(5):317-21. DOI: 10.1177/096032719000900509. View

17.

Hanna M, Peat S, Woodham M, Knibb A, Fung C . Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine. Br J Anaesth. 1990; 64(5):547-50. DOI: 10.1093/bja/64.5.547. View

18.

Rothman R, JACOBSON A, Rice K, Herkenham M . Autoradiographic evidence for two classes of mu opioid binding sites in rat brain using [125I]FK33824. Peptides. 1987; 8(6):1015-21. DOI: 10.1016/0196-9781(87)90130-6. View

19.

Osborne R, Joel S, TREW D, Slevin M . Analgesic activity of morphine-6-glucuronide. Lancet. 1988; 1(8589):828. DOI: 10.1016/s0140-6736(88)91691-1. View

20.

Oguri K, Shigezane J, Hirano T, Yoshimura H . Enhanced binding of morphine and nalorphine to opioid delta receptor by glucuronate and sulfate conjugations at the 6-position. Life Sci. 1987; 41(12):1457-64. DOI: 10.1016/0024-3205(87)90710-7. View